

**3<sup>rd</sup> International PPRI Conference**  
**Pharmaceutical Pricing and Reimbursement Policies**  
**Challenges Beyond the Financial Crisis**

Vienna, 12-13 October 2015



# Conference Programme



WHO Collaborating Centre  
for Pharmaceutical Pricing  
and Reimbursement Policies



**PPRI**  
Pharmaceutical Pricing and  
Reimbursement Information

Gesundheit Österreich  
GmbH ● ● ●

**International PPRI Conference  
12–13 October 2015, Vienna**

**Venue**

Palais Niederösterreich, Herrengasse 13, 1010 Vienna, Austria

**Organiser**

The PPPRI conference is organised by the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies affiliated to the Health Economics Department of Gesundheit Österreich GmbH (GÖG/Austrian Public Health Institute) in Vienna.

Conference website: <http://whocc.goeg.at/Conference2015>

Contact: [ppriconference@goeg.at](mailto:ppriconference@goeg.at)

**Disclaimer**

The Gesundheit Österreich GmbH (GÖG/Austrian Public Health Institute) is responsible for the content of this programme. The views and opinions expressed in the course of the PPRI conference are those of the speakers, panelists, facilitators and participants and do not necessarily reflect the official policy or position of the World Health Organization (WHO). The conference is not an event of WHO.

Please note that it is not allowed to take pictures, audio-records and videos during the conference.

Images will be captured during the event by a photographer commissioned by the organiser and may be used on the conference website or in publications reporting the outcome of the conference. For practical reasons it is not possible to seek written consent to image capture from all persons at the PPRI Conference 2015. Unless express objections are received, individuals attending the conference are deemed to have given their consent by attending or remaining at the event. Any queries or complaints should be raised with the organiser in the first instance.

© 2015 WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies affiliated to the Health Economics Department at Gesundheit Österreich GmbH (GÖG/Austrian Public Health Institute) in Vienna

- **Conference registration desk**

The conference registration desk is situated on the ground floor of Palais Niederösterreich, next to the main entrance. In case of any queries regarding the organisation of the conference, please consult the staff at the registration desk.

- **Attendance certificate**

An attendance certificate can be found at the conference registration desk. Please do not forget to take your certificate with you.

- **Internet access**

Internet is accessible via wireless LAN: PalaisNOE\_free (access without Code, 0,4 Mbit/User).

- **Poster exhibition**

During both conference days, **posters of accepted abstracts** (Monday) and **country posters of national pharmaceutical systems** (Tuesday) are displayed (see map below). These posters are included in the **Abstract Poster Book** and the **Country Poster Book**. Authors of the posters are available for questions next to their posters during the dedicated poster walks (Mon, 15.15–15.45 and Tue, 10.00–10.30).

- **Presentations and posters**

Presentations and posters presented at the conference will be available for download after the event at the website: <http://whocc.goeg.at/Conference2015/Programme>.

- **Guided tour**


A guided tour of the Landtagssaal will be offered. Meet at the Vienna information corner on Tue, 13.00.

- **Vienna information corner**

For information about Vienna (i.e. sightseeing, public transport), please consult the Vienna information corner, located on the first floor before entering Prälatensaal.



## First Floor



	<b>Monday, 12 October 2015</b>
<b>8.00–9.00</b>	<b>Registration and Coffee</b>
<b>9.00–10.00</b> LANDTAGSSAAL	<b>Welcome</b> Minister Sabine Oberhauser, Austrian Federal Ministry of Health General Manager Georg Ziniel, Gesundheit Österreich GmbH (GÖG/Austrian Public Health Institute) Director of the Essential Medicines and Health Products Department Kees de Joncheere, World Health Organization (WHO) Headquarters Head of WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies Sabine Vogler, GÖG/Austrian Public Health Institute <b>Facilitator:</b> Lena Lepuschütz, GÖG/Austrian Public Health Institute
<b>10.00–10.45</b> LANDTAGSSAAL	<b>Key Note:</b> <b>Affordable Innovation – Future Directions in Pharmaceutical Policy</b> Suzanne Hill, Senior Adviser, Policy Access and Use, Essential Medicines and Health Products Department, WHO HQ, Switzerland  <b>Commentary:</b> Menno Arnout, International Association of Mutual Benefit Societies (AIM) Valérie Paris, Organisation for Economic Co-operation and Development (OECD), France <b>Facilitator:</b> Lena Lepuschütz, GÖG/Austrian Public Health Institute
<b>10.45–11.15</b> RITTERSAAL	<b>Coffee Break</b>
<b>11.15–12.15</b> LANDTAGSSAAL	<b>Stakeholder Roundtable: Pharmaceutical Policies in Crisis? Needs for Change</b>  <b>Panelists</b> Francis Arickx, Social Health Insurance (INAMI), Belgium Richard Bergström, European Federation of Pharmaceutical Industries and Associations (EFPIA) Tim Reed, Health Action International (HAI) Global Jan Mazag, State Institute for Drug Control (SUKL), Slovakia  <b>Commentary:</b> Pieter Dylst, European Generic and Biosimilar Medicines Association (EGA)  <b>Facilitator:</b> Hans Hogerzeil, University Groningen, The Netherlands
<b>12.15–12.30</b> LANDTAGSSAAL	<b>Outlook on Conference</b> Lena Lepuschütz, GÖG/Austrian Public Health Institute

	<b>Monday, 12 October 2015</b>
<b>12.30–14.00</b> RITTERSAAL	<b>Lunch Break</b>
<b>14.00–15.15</b>	<b>Breakout Session (Strand I – Strand III)</b>
LANDTAGSSAAL	<p><b>Strand I: Challenges and Opportunities for Pharmaceutical Policies</b></p> <p><b>Key Note:</b> Priority Medicines for Europe and the World: Setting a public–health–based medicines development agenda Veronika Wirtz, Boston University, USA</p> <p><b>Abstract Presentation:</b> Adapting pharmaceutical reimbursement policies to manage spending on high–priced drugs Elizabeth Docteur, Elizabeth Docteur Consulting, USA</p> <p><b>Abstract Presentation:</b> Financial based agreements and performance based agreements: the Belgian experience Kim Pauwels, KU Leuven, Belgium (Young Researcher Award)</p> <p><b>Facilitator:</b> Christine Leopold, Harvard Medical School and Harvard Pilgrim Institute, USA</p>
HERRENSAAL	<p><b>Strand II: Policies beyond the Crisis: Lessons Learned</b></p> <p><b>Key Note:</b> Pharmaceutical Policies in Australia and New Zealand Zaheer–Ud–Din Babar, University of Auckland, New Zealand</p> <p><b>Abstract Presentation:</b> Highly innovative drugs in the Czech Republic: retrospective analysis of impact on early market entry, regular reimbursement system entry and public pharmaceutical expenditure Juraj Slabý, State Institute for Drug Control (SIDC), Czech Republic</p> <p><b>Abstract Presentation:</b> Impact of discounts on medicine prices Peter Schneider, GÖG/Austrian Public Health Institute</p> <p><b>Facilitator:</b> Suzanne Hill, Senior Adviser, Policy Access and Use, Essential Medicines and Health Products Department, WHO HQ, Switzerland</p>
PRÄLATENSAAL	<p><b>Strand III: Policy Cooperation and Interface Issues</b></p> <p><b>Key Note:</b> Scottish collaboration to integrate medicine therapy between out–patient and in–patient sectors Ken Paterson, University of Glasgow, Scotland</p> <p><b>Abstract Presentation 1:</b> Determinants of differences in utilisation of cancer medicines in Belgium, Scotland and Sweden. Alessandra Ferrario, London School of Economics (LSE), England</p> <p><b>Abstract Presentation 2:</b> A cost/benefit analysis of self–care initiatives in the European Union – who gains, who loses? Julia Bobek, GÖG/Austrian Public Health Institute</p> <p><b>Facilitator:</b> Sabine Vogler, WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, GÖG/Austrian Public Health Institute</p>

	<b>Monday, 12 October 2015</b>
<b>15.15–15.45</b>	<b>Poster walk during the coffee break</b> Authors are available next to the posters for questions  Posters of authors A–U in RITTERSAAL Posters of authors V–Z in the rooms before entering the PRÄLATENSAAL (see map about the first floor)
<b>15.45 –17.00</b>	<b>Moderated Poster Session</b>
LANDTAGSSAAL	<b>Strand I: Challenges and Opportunities for Pharmaceutical Policies</b> <ul style="list-style-type: none"> <li>• Unintended consequences of co-payment regulations in Belgium: the case of atorvastatin Jessica Fraeyman, Department of Epidemiology and Social Medicine, Research Unit of Medical Sociology and Health Policy, University Antwerp, Belgium</li> <li>• Impact of Generic Price Linkage System and Reference Price System on Prices of Pharmaceuticals – Comparison of Austria and Finland Jaana Martikainen, Social Insurance Institution, Finland</li> <li>• Availability and prices of essential medicines for chronic diseases in older people in the Asia Pacific Region Agnes Vitry, University of South Australia, Australia</li> <li>• Unintended consequences of pharmaceutical policies: A three country qualitative study of Namibia, South Africa and Ghana insurance reimbursement models Emmanuel K Eghan, Management Sciences for Health (MSH), USA</li> </ul> <b>Facilitator:</b> Anna Bucsics, University of Vienna, Austria
PRÄLATENSAAL	<b>Strand II: Policies beyond the Crisis: Lessons Learned</b> <ul style="list-style-type: none"> <li>• Transitioning to a national health system in Cyprus: a stakeholder analysis of pharmaceutical policy reform Olivier Wouters, London School of Economics (LSE), England</li> <li>• Impact of delisting OTC medicines from reimbursement list in Czech Republic Petra Chytilová, State Institute of Drug Control (SIDC), Czech Republic</li> <li>• The impact of Ghana's National Health Insurance Scheme (NHIS) median pharmaceutical pricing methodology and reimbursement policy on the pharmaceutical system Dumebi Mordi, Management Sciences for Health (MSH), USA</li> <li>• The Effect of Pricing Regulation on Prescription Frequency of Compounded Drugs, Medical Foods, and Convenience Packages in the US Tracy Lin, University of California, USA</li> </ul> <b>Facilitator:</b> Valérie Paris, OECD, France

	<b>Monday, 12 October 2015</b>
HERRENSAAL	<b>Strand III: Policy Cooperation and Interface Issues</b> <ul style="list-style-type: none"> <li>Retrospective financial analysis of medicines reimbursement services in community pharmacy Elena Chitan, State University of Medicine and Pharmacy 'Nicolae Testemitanu', Moldova</li> <li>Multi-Indication Pricing: Pros, Cons and Applicability to the UK Jorge Mestre-Ferrandiz, Office of Health Economics (OHE), England</li> <li>A forecasting model for drug utilization and expenditure integrating a Cellular Automata model with the Budget Impact Analysis approach. Preliminary results. Roberta Joppi, Local Health Authority of Verona – Veneto region, Italy</li> <li>Policy options to deal with high-cost medicines – Survey with European policy-makers Nina Zimmermann, GÖG (Austrian Public Health Institute), Austria</li> </ul> <b>Facilitator:</b> Veronika Wirtz, Boston University, USA
<b>17.00–17.30</b> LANDTAGSSAAL	<b>Key Note:</b> <b>New WHO Report ‘Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research’</b> Hanne Bak Pedersen, WHO Regional Office for Europe, Denmark <b>Facilitator:</b> Aukje Mantel-Teeuwisse, Utrecht University, The Netherlands
<b>17.30–18.30</b> RITTERSAAL	<b>Reception</b>



	<b>Tuesday, 13 October 2015</b>
<b>8.00–9:00</b> HERRENSAAL	<b>Early Bird Session: Meet the Editors</b> <ul style="list-style-type: none"> <li>Journal of Pharmaceutical Policy and Practice (JOPPP), Zaheer-Ud-Din Babar</li> <li>PharmacoEconomics, Chris Carswell (online)</li> <li>Health Policy, Panos Kanavos</li> <li>Generics and Biosimilars Initiative Journal (GaBI), Arnold Vulto</li> <li>Bulletin of the World Health Organization, Laragh Gollogly</li> </ul> <b>Facilitator:</b> Aukje Mantel-Teeuwisse, Utrecht University, The Netherlands
<b>9.00–10.00</b>	<b>Country Poster Presentations</b>
LANDTAGSSAAL	<b>European Union</b> <ul style="list-style-type: none"> <li><b>Austria:</b> Margit Gombocz, GÖG/Austrian Public Health Institute and Robert Sauermann, Main Association of Austrian Social Security Institutions (MASSI)</li> <li><b>Cyprus:</b> Helena Panayiotopoulou, Pharmaceutical Services, Ministry of Health</li> <li><b>Ireland:</b> Kate Mulvenna, Health Service Executive</li> <li><b>Sweden:</b> Peter Skiöld, The Dental and Pharmaceutical Benefits Agency (TLV)</li> </ul> <b>Facilitator:</b> Robin Šebesta, State Institute for Drug Control, Czech Republic
HERRENSAAL	<b>Other European Countries</b> <ul style="list-style-type: none"> <li><b>Norway:</b> Helga Festøy, Norwegian Medicines Agency</li> <li><b>Russia:</b> Liudmila Bezmelnitsyna, National Institution for Public Health</li> <li><b>Switzerland:</b> Jörg Indermitte, Federal Office of Public Health</li> <li><b>Ukraine:</b> Olga Sadovnycha, State Expert Centre of the Ministry of Health</li> </ul> <b>Facilitator:</b> Guillaume Dedet, WHO Regional Office for Europe, Denmark
PRÄLATENSAAL	<b>Non-European Countries</b> <ul style="list-style-type: none"> <li><b>Canada:</b> Tanya Potashnik, Patented Medicine Prices Review Board (PMPRB)</li> <li><b>Colombia:</b> Angela Acosta Santamaria, Pontificia Universidad Javeriana</li> <li><b>Mexico:</b> Yared Santa-Ana-Tellez, Utrecht University, The Netherlands</li> <li><b>South Africa:</b> Ntobeko Mpanza, National Department of Health of South Africa</li> </ul> <b>Facilitator:</b> Veronika Wirtz, Boston University, USA
<b>10.00–10.30</b>	<b>Poster walk during the coffee break</b> <p>Authors are available next to the posters for questions</p> <p>Posters of <b>EU/EEA</b> and <b>Switzerland</b> in RITTERSAAL</p> <p>Posters of other European countries and <b>Australia</b> and <b>Malaysia</b> in room before GOTISCHES ZIMMER</p> <p>Posters of other <b>non-European countries</b> in GOTISCHES ZIMMER</p> <p>(see map about the first floor)</p>



	<b>Tuesday, 13 October 2015</b>
<b>10.30–12.00</b>	<b>Breakout Session (Strand I – III)</b>
PRÄLATENSAAL	<p><b>Strand I: Challenges and Opportunities for Pharmaceutical Policies</b>  <b>Key Note:</b> Biosimilars: Same quality, lower price, improved patient access  Arnold Vulto, Erasmus University Hospital, The Netherlands</p> <p><b>Abstract Presentation:</b> Access to subsidised medicines, cost of medicines and health outcomes: Exploring general practitioners' perceptions and experiences  Zaheer-Ud-Din Babar, University of Auckland, New Zealand</p> <p><b>Abstract Presentation:</b> Using a Multiple Criteria Decision Analysis (MCDA) framework to make coverage decisions: an experimental case study on metastatic colorectal cancer  Aris Angelis, London School of Economics (LSE), England</p> <p><b>Abstract Presentation:</b> Approval, reimbursement and pricing of high cost cancer medicines in Australia  Agnes Vitry, University of South Australia, Australia</p> <p><b>Facilitator:</b> Hanne Bak Pedersen, WHO Regional Office for Europe, Denmark</p>
HERRENSAAL	<p><b>Strand II: Policies beyond the Crisis: Lessons Learned</b>  <b>Key Note:</b> The Greek experience – Lessons learned  Panos Kanavos, London School of Economics (LSE), England</p> <p><b>Abstract Presentation:</b> Introduction of generic substitution and reference pricing in Ireland: early effects on state pharmaceutical expenditure and generic penetration, and associated success factors  Susan Spillane, National Centre for Pharmacoeconomics, Ireland</p> <p><b>Abstract Presentation:</b> Price changes of antibiotics and perceived substitutes in the context of OTC policy changes in Mexico and Brazil  Yared Santa-Ana-Tellez, Utrecht University, The Netherlands</p> <p><b>Abstract Presentation:</b> Socioeconomic Determinants of Medicines Use in Central Eastern Europe: The Role of Pharmaceutical Policy in Reducing Inequalities  Susanne Mayer, Department of Health Economics, Centre for Public Health, Medical University of Vienna, Austria</p> <p><b>Facilitator:</b> Aukje Mantel-Teeuwisse, Utrecht University, The Netherlands</p>
LANDTAGSSAAL	<p><b>Strand III: Policy Cooperation and Interface Issues</b>  <b>Key Note:</b> The Sofosbuvir case – Lessons learned  Florent Dromzée, Ministry of Health, France</p> <p><b>Abstract Presentation:</b> Why we should have more collaboration on HTA in Europe: The example of sofosbuvir  Wim Goettsch, National Health Care Institute, The Netherlands</p> <p><b>Abstract Presentation:</b> Criteria for Inclusion into the Essential Medicines List  Nicola Magrini, World Health Organization, Switzerland</p> <p><b>Abstract Presentation:</b> Collaborative models for increasing efficiency of early drug assessment  Anna Nachtnebel, Ludwig Boltzmann Institute for Health Technology Assessment, Austria</p> <p><b>Facilitator:</b> Hans Hogerzeil, University Groningen, The Netherlands</p>

	<b>Tuesday, 13 October 2015</b>
<b>12.00–13.30</b> RITTERSAAL	<b>Lunch</b>
<b>13.30–15.30</b> LANDTAGSSAAL	<b>Afternoon session</b> <b>Facilitator:</b> Kees de Joncheere, WHO HQ, Switzerland
<b>13.30–14.30</b>	<b>Key Note: Perspectives for the Future</b> Andy Gray, University of KwaZulu–Natal, South Africa
<b>14.30–15.00</b>	<b>Closing Commentary: Patients have the last word?</b> Nicola Bedington, European Patients' Forum (EPF)
<b>15.00–15.30</b>	<b>Conclusions, awards and closure</b> Sabine Vogler, WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, GÖG/Austrian Public Health Institute

Special thanks go to the members of the Scientific Programme Committee who contributed their expertise and dedication to this event.

<b>Name</b>	<b>Institution</b>	<b>Country</b>
<b>Mr Zaheer–Ud–Din Babar</b>	University of Auckland	New Zealand
<b>Ms Hanne Bak Pedersen</b>	World Health Organization, Regional Office for Europe	Denmark
<b>Ms Alessandra Ferrario</b>	London School of Economics (LSE)	England
<b>Mr Kees de Joncheere</b>	World Health Organization, Headquarters	Switzerland
<b>Mr Panos Kanavos</b>	London School of Economics (LSE)	England
<b>Ms Lena Lepuschütz</b>	GÖG/Austrian Public Health Institute, WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies	Austria
<b>Ms Aukje Mantel–Teeuwisse</b>	Utrecht University, WHO Collaborating Centre for Pharmaceutical Policy and Regulation	The Netherlands
<b>Ms Valérie Paris</b>	Organisation for Economic Co–operation and Development (OECD)	France
<b>Ms Sabine Vogler</b>	GÖG/Austrian Public Health Institute, WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies	Austria
<b>Ms Veronika Wirtz</b>	Boston University	United States
<b>Ms Nina Zimmermann</b>	GÖG/Austrian Public Health Institute, WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies	Austria

## About the organisers

In July 2010, the World Health Organization (WHO) nominated the Health Economics Department at Gesundheit Österreich GmbH (GÖG/Austrian Public Health Institute) as a WHO Collaborating Centre and re-designated it for another four years in June 2014. WHO Collaborating Centres are institutions such as research institutes, parts of universities or academies, which are designated by the WHO Director-General to carry out activities in support of the Organization's programmes. Currently, there are two WHO Collaborating Centres in Austria.

The **WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies** has a dedicated team of academics working closely with the WHO at international and European levels to facilitate the development of a public health approach in pharmaceutical pricing and reimbursement policies through research, exchange and dissemination of the evidence base of best-practice models and knowledge transfer. The expertise at this WHO Collaborating Centre has been established during the last two decades in the framework of numerous national and international projects, initiatives and networks.

A particular initiative in this context is the **Pharmaceutical Pricing and Reimbursement Information (PPRI)** network that celebrates its 10<sup>th</sup> anniversary in 2015. PPRI was originally a European Commission co-funded project (2005 – 2007) that aimed to improve information and knowledge on pharmaceutical systems in Europe since no such initiative existed at that time. In the course of the project, the PPRI network of competent authorities was established, and a set of pharmaceutical indicators, filled with real data from the then 28 PPRI countries, as well as more than 20 country reports and brief overviews on the pharmaceutical systems (country information) were produced. Since 2008, PPRI has continued as a Member States driven initiative because policy makers represented in the PPRI network expressed their strong interest to continue collaboration. The PPRI Secretariat is hosted at GÖG/Austrian Public Health Institute and is funded by the Austrian Federal Ministry of Health.

In 2011, the PPRI project was selected by the Executive Agency for Health and Consumers, in collaboration with the Health Programme's National Focal Points and the Directorate General for Health and Consumers of the European Commission as a good practice example of a EU Public Health project with an important impact for EU Member States.

Eligible institutions for the PPRI network are competent authorities for pharmaceutical pricing and reimbursement. As of October 2015, the PPRI network comprises around 90 institutions from 46 countries (all 28 EU Member States, plus Armenia, Albania, Belarus, Canada, Macedonia, Moldova, Norway, Iceland, Israel, Kazakhstan, Kyrgyzstan, Russia, Switzerland, Serbia, South Africa, South Korea, Turkey, and Ukraine) and European Commission services and agencies, OECD, WHO and the World Bank. For further information see <http://whocc.goeg.at>.